JBJohannes Blumenstein

Johannes Blumenstein

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Johannes Blumenstein has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • TCT-34 Prediction of acute kidney injury after TAVR by new biomarkers

    by Mani Arsalan, Matthias Renker, Luise Gaede, Maren Weferling, Arnaud Van Linden, Johannes Blumenstein, Helge Möllmann, Mirko Doss, Karl Lackner, Giovanni Filardo, et al.

  • Challenges of coronary angiography and intervention in patients previously treated by TAVI

    by Johannes Blumenstein, Won-Keun Kim, Christoph Liebetrau, Luise Gaede, Joerg Kempfert, Thomas Walther, Christian Hamm, Helge Möllmann

    Since the beginning of the transcatheter aortic valve implantation (TAVI) era, many prosthetic valves have entered clinical practice. TAVI prostheses differ regarding stent design and some may potentially interfere with diagnostic or interventional catheters. The aim of our analysis was to evaluate the feasibility of coronary angiography (CA) or percutaneous coronary intervention (PCI) in patients with prior TAVI.


  • Open Access

    Recent Advances in Transcatheter Aortic Valve Implantation: Novel Devices and Potential Shortcomings

    by J. Blumenstein, C. Liebetrau, A. Linden, H. Moellmann, T. Walther, J. Kempfert

    During the past years transcatheter aortic valve implantation (TAVI) has evolved to a standard technique for the treatment of high risk patients suffering from severe aortic stenosis. Worldwide the number of TAVI procedures is increasing exponentially. In this context both the transapical antegrade (TA) and the transfemoral retrograde (TF) approach are predominantly used and can be considered as safe and reproducible access sites for TAVI interventions. As a new technology TAVI is in a constant progress regarding the development of new devices. While in the first years only the Edwards SAPIENTM and the Medtronic CoreValveTM prostheses were commercial available, recently additional devices obtained CE-mark approval and others have entered initial clinical trials. In addition to enhance the treatment options in general, the main driving factor to further develop new device iterations is to solve the drawbacks of the current TAVI systems: paravalvular leaks, occurrence of AV-blocks and the lack of full repositionability.


    • 2 December 2013

    Transcatheter Heart Valves: Specific Characteristics and Potential Shortcomings.

    by J Blumenstein, A Van Linden, H Moellmann, T Walther, J Kempfert

    During the past years TAVI has evolved to a standard technique for the treatment of high risk patients suffering from severe aortic stenosis. Worldwide the number of TAVI procedures is increasing exponentially. In this context both the transapical antegrade (TA) and the transfemoral retrograde (TF) approach are predominantly used and can be considered as safe and reproducible access sites for TAVI interventions. As a new technology TAVI is in a constant progress regarding the development of new devices. While in the first years only the Edwards SAPIEN™ and the Medtronic CoreValve™ prostheses were commercial available, recently additional devices obtained CE-mark approval and others have entered initial clinical trials. In addition to enhance the treatment options in general, the main driving factor to further develop new device iterations is to solve the drawbacks of the current TAVI systems: paravalvular leaks, occurrence of AV-blocks and the lack of full repositionability.

  • Open Access

    Impact of bubble size in a rat model of cerebral air microembolization

    by Martin Juenemann, Mesut Yeniguen, Nadine Schleicher, Johannes Blumenstein, Max Nedelmann, Marlene Tschernatsch, Georg Bachmann, Manfred Kaps, Petr Urbanek, Markus Schoenburg, et al.

    Background: Cerebral air microembolization (CAM) is a frequent side effect of diagnostic or therapeutic interventions. Besides reduction of the amount of bubbles, filter systems in the clinical setting may also lead to a dispersion of large gas bubbles and therefore to an increase of the gas–liquid-endothelium interface. We evaluated the production and application of different strictly defined bubble diameters in a rat model of CAM and assessed functional outcome and infarct volumes in relation to the bubble diameter. Methods: Gas emboli of defined number and diameter were injected into the carotid artery of rats. Group I (n = 7) received 1800 air bubbles with a diameter of 45 μm, group II (n = 7) 40 bubbles of 160 μm, controls (n = 6) saline without gas bubbles; group I and II yielded the same total injection volume of air with 86 nl. Functional outcome was assessed at baseline, after 4 h and 24 h following cerebral MR imaging and infarct size calculation. Results: Computer-aided evaluation of bubble diameters showed high constancy (group I: 45.83 μm ± 2.79; group II: 159 μm ± 1.26). Animals in group I and II suffered cerebral ischemia and clinical deterioration without significant difference. Infarct sizes did not differ significantly between the two groups (p = 0.931 u-test). Conclusions: We present further development of a new method, which allows reliable and controlled CAM with different bubble diameters, producing neurological deficits due to unilateral cerebral damage. Our findings could not display a strong dependency of stroke frequency and severity on bubble diameter.


  • Open Access

    First-in-man evaluation of the transapical APICA ASC access and closure device: the initial 10 patients

    by Johannes Blumenstein, Joerg Kempfert, Arnaud Van Linden, Mani Arsalan, Sina K. Schmidt, Helge Mollmann, Won-Keun Kim, Vinod Thourani, Thomas Walther

    The aim of this study was to evaluate the initial and short-term results of a new apical access and closure device to facilitate and standardize the transapical (TA) approach to transcatheter aortic valve implantation (TAVI). The apical access, stabilization and closure (ASC™) device consists of three components: an introducer system, a left ventricular low-profile titanium coil and a closure cap. The ASC™ introducer system is anchored and rotated into the myocardium almost like a corkscrew, using the titanium coil. Following the TA-AVI procedure, the closure cap is introduced and delivered through the system into the titanium coil for final sealing. A total of 11 high-risk elderly patients (EuroSCORE I: 27.8 ± 16.7; EuroSCORE II: 6.6 ± 5.0 and The Society of Thoracic Surgeons (STS) score: 5.9 ± 2.7%) were evaluated for TA-AVI by our interdisciplinary Heart Team and subsequently included in the trial after informed consent was obtained. One patient was excluded due to the presence of deep epicardial fat tissue. In all other cases, the titanium coil provided sufficient sealing throughout the procedure without the presence of perisheath bleeding. After delivery of the closure cap, no relevant bleeding was observed in any patient. Pericardial drainages were removed early in all patients. One patient suffered from non-device-related pericardial effusion requiring surgical decompression on postoperative day 6. Two patients suffered from delayed minor strokes, most likely due to arrhythmia. All patients received aspirin, clopidogrel and low molecular heparin after the procedure. Discharge echocardiography revealed no changes in left ventricular function when compared with baseline and no new onset wall motion abnormalities. All 10 patients were alive at 30 days. TA access and closure are both feasible and safe using the APICA ASC™ device. The system facilitates and standardizes TA access and closure by providing a sufficient and secure sealing during and after the TA-AVI procedure.


  • DynaCT-Guided Anatomical Rotation of the SAPIEN XT Valve during Transapical Aortic Valve Implantation: Proof of Concept

    by Arnaud Van Linden, Helge Moellmann, Joerg Seeburger, Ardawan Rastan, Won-Keung Kim, Friedrich W. Mohr, Joerg Kempfert, Thomas Walther, Johannes M. Blumenstein

    Background Transcatheter aortic valve implantation (T-AVI) by using the Edwards SAPIEN (Edwards Lifesciences LLC, Irvine, California, United States) prosthesis is currently being performed by the implantation of valved stent into the aortic annulus without respecting the native commissural (rotational) orientation. Anatomical orientation may, however, be beneficial regarding optimal physiological valve performance, optimal coronary flow, and avoidance of the fully covered commissural stent part in front of the coronary ostia. With the recently introduced SAPIEN XT, transcatheter valve identification of the commissures during fluoroscopy is feasible. The aim of this study was to evaluate the concept of Dynamic-CT (DynaCT)–guided anatomical rotation of the SAPIEN XT valve during transapical-AVI (TA-AVI). Methods Intraoperatively, an automatically segmented DynaCT was performed using the Siemens Syngo Aortic ValveGuide (Siemens AG, Forchheim, Germany) software prototype. Commissures of SAPIEN XT could be identified with a high-quality fluoroscopic system. Before standard TA implantation, one radiopaque stent commissure of the crimped SAPIEN XT prosthesis was aligned with the native aortic valve commissure visualized by DynaCT. Resulting rotational orientation of the valve after implantation was assessed by transesophageal echocardiography. Results Feasibility of anatomical rotation was evaluated in 10 patients scheduled for TA-AVI by an interdisciplinary heart team. Mean logistic EuroSCOREs and Society of Thoracic Surgeons scores were 23.7 ± 4.9% and 8.6 ± 2.1%, mean aortic gradient improved from 46.0 ± 21.9 to 9.6 ± 3.1 mm Hg, and there was no death within 30 days. All valves were implanted successfully with none or trivial paravalvular regurgitation in seven patients, mild (1 + ) in two patients, and moderate (2 + ) in one patient. An optimal anatomical position could be achieved in six patients, minor rotational deviation (< 10 degrees) in three patients, and moderate deviation (10 to 20 degrees) in one patient only. Conclusions DynaCT-guided anatomical rotation of the SAPIEN XT valve is feasible during TA-AVI, avoiding implantation of the fully covered commissural posts in front of the coronary ostia. This might reduce the risk of coronary obstruction. In addition, the technique provides the potential benefit of physiological valve position and performance.


  • Experimental Evaluation of a New Apical Access and Closure Device

    by Johannes Blumenstein, Arnaud Van Linden, Mani Arsalan, Sandra Voss, Helge Moellmann, Christoph Liebetrau, Vinod H. Thourani, Thomas Walther, Joerg Kempfert


  • Early SAPIEN transcatheter heart valve dysfunction due to tissue ingrowth in an octogenarian

    by J. Blumenstein, A. Van Linden, Won-Keun Kim, W. Skwara, M. Schoenburg, M. Arsalan, H. Moellmann, M. Niederhagen, J. Kempfert, T. Walther


  • Retrograde, transsubclavian implantation of a SAPIEN XT™ aortic valve prosthesis with the Edwards NovaFlex+™ system

    by J. Blumenstein, A. Van Linden, J. Kempfert, Woung-Keung Kim, C. Liebetrau, C. Hamm, H. Nef, T. Walther, H. Moellmann